CCL17 and Alzheimer disease: Notably, among blood cytokines, TARC, also known as CCL17 and recognized as pivotal AD clinical biomarkers [37, 38], exhibited substantial differences in the study group relative to the placebo cohort at the 16-week mark following administration of the investigational drug.